Resonance Health looks to patent liver fibrosis test using magnetic resonance imaging

By Angela McDaniels

Seattle, Nov. 3 - The Resonance Health Group said it has filed a new U.S. patent application for a non-invasive measure of liver structure with direct application to the non-invasive diagnosis of liver fibrosis.

Following completion of the current research program, which was supported through the Australian Commonwealth Government's Biotechnology Innovation Fund, Resonance Health said it will shift its focus toward the clinical development and commercialization of a non-invasive test for fibrosis using magnetic resonance imaging technology.

The company launched a similar non-invasive liver diagnostic product earlier this year, FerriScan.

"Meeting an immediate clinical need, this new test will significantly expand the company's market opportunity, whilst leveraging off infrastructure and resources already in place for the commercial roll-out of FerriScan," said James Williams, managing director of Resonance Health, in a news release.

Resonance Health is a Nedlands, Australia-based health care company specializing in the development of magnetic resonance imaging-related technology for the quantitative measurement of iron levels in the body.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.